Compounded Transdermal Cream Multi-Drug Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional transdermal creams have limitations such as addressing only limited medical conditions, causing adverse side effects, and having short shelf lives, along with inefficient manufacturing processes that lack precision in active ingredient amounts.
Innovation Solution
A compounded transdermal cream is formulated by combining a diclofenac sodium solution with a lidocaine and prilocaine cream, along with a fine powder of additional medications like lamotrigine, topiramate, or gabapentin, to create a cream with precise concentrations of active ingredients, minimizing adverse reactions and extending storage stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional transdermal creams are used, then they are simple to manufacture, but they address limited medical conditions and cause adverse side effects
Solution Approach 1:
The patent combines multiple separate medications (diclofenac sodium, lidocaine, prilocaine, and additional medications like lamotrigine, topiramate, or gabapentin) into a single transdermal cream formulation. This merging approach allows the cream to address multiple medical conditions simultaneously (pain, inflammation, neuropathy, epilepsy) while maintaining a unified manufacturing process that mixes components together, thus increasing versatility without proportionally increasing manufacturing complexity
Solution Approach 2:
The transdermal cream is designed with universal applicability to treat multiple different medical conditions through a single product. By incorporating a base cream with lidocaine and prilocaine for pain relief, diclofenac sodium for anti-inflammatory effects, and optional additional medications for specific conditions like neuropathy or epilepsy, the formulation achieves multi-functionality that reduces the need for multiple separate treatments
2Duration of action of stationary object
If conventional transdermal creams are used, then the formulation is simple, but they have short shelf lives
Solution Approach 1:
The patent employs preliminary stabilization measures by incorporating specific excipients and preservatives into the cream formulation during the manufacturing process. The base cream and additional components are pre-formulated with stability-enhancing ingredients that prevent degradation of the active medications (diclofenac sodium, lidocaine, prilocaine) over time, thereby extending shelf life while maintaining a relatively straightforward formulation process
Solution Approach 2:
The transdermal cream utilizes a composite formulation structure combining multiple cream bases and active ingredients with complementary stability properties. The combination of lidocaine-prilocaine base cream, diclofenac sodium solution, and additional medications creates a synergistic formulation where each component contributes to overall formulation stability, extending shelf life through material composition rather than complex processing
3Manufacturing precision
If conventional manufacturing methods are used, then the process is efficient, but they lack precision with the amount of active ingredients
Solution Approach 1:
The manufacturing process is segmented into distinct mixing stages: first combining the base cream with lidocaine and prilocaine, then separately incorporating diclofenac sodium solution, and finally adding additional medications like lamotrigine, topiramate, or gabapentin. This segmentation allows for precise control and measurement of each active ingredient's quantity during the compounding process, ensuring accurate dosing while maintaining a systematic and efficient overall manufacturing workflow
Data Source
AI summary
A method of producing a compounded medication may include formulating a compounded transdermal cream that includes combining a diclofenac sodium solution and a lidocaine and prilocaine cream. The diclofenac sodium solution may be combined in an amount providing a diclofenac concentration of between approximately 0.1% and approximately 0.75% by weight of the compounded transdermal cream. The lidocaine and prilocaine cream may be combined in an amount providing an approximate equivalent concentration of each of lidocaine and prilocaine between approximately 1.5% and approximately 2.25% by weight of the compounded transdermal cream.